

# I want my treatment!

Jan Boone

February 27th, 2016

Introduction

Health insurance

Economic analysis

Conclusion

# Introduction

## two definitions

- ▶ Economics analyzes the allocation of scarce resources
- ▶ Economists know the price of everything and the value of nothing
- ▶ both are relevant in health care
- ▶ “financial considerations should play no role in health care”


# why worry?

# value

- ▶ growth does not mean anything (good or bad)
- ▶ value is important
- ▶ is there reason to believe we lose value in health care?

## examples

- ▶ strong preference for treatment (even if it does not do anything) than to do nothing



# Health insurance



## moral hazard

- ▶ we have (mandatory) health insurance because
  - ▶ treatments are expensive and you may not be able to afford them
  - ▶ if you could afford the treatments, big reduction in “normal” consumption
  - ▶ solidarity: some people are unlucky with their health and we all pay for their treatments
- ▶ problem is that health becomes (almost) free
- ▶ when something is free, people tend to behave in “strange” ways

## solutions

- ▶ higher copayment
  - ▶ insurance: people are risk averse
  - ▶ solidarity: chronically ill have to pay more
- ▶ exclude some treatments
- ▶ in the news:
  - ▶ “Advies: borstkankermiddel niet vergoeden”, NRC 21-1-2016
  - ▶ “Bestraling van kanker kan beter maar kost wel 10.000 euro meer”, NRC 5-3-2015
  - ▶ “Longkankermedicijn is te duur voor basispakket, vindt Zorginstituut”, NRC 8-12-2015
  - ▶ “Pompe wel of niet in het basispakket, dat is de vraag”, NRC 22-9-2012
  - ▶ “Duur medicijn voor SLE-patient afgewezen voor vergoeding”, NRC 11-9-2012

## Economic analysis

## scarce resources

- ▶ we can spend each euro only once
- ▶ should we spend it on education, welfare benefits, the army, health care, consumption (lower taxes)?
- ▶ return on education is estimated to be around 15% per euro
- ▶ what is the return on health care expenditure?
- ▶ within health: if we face a budget, which treatments should we spend money on?

## value of health

- ▶ suppose a treatment increases your life with exactly one year
- ▶ what is this worth to you?

- ▶ in the Netherlands we work with 80.000 euro
- ▶ the UK with 25.000 pound
- ▶ economic analysis finds something in the range 100.000-200.000
- ▶ we are trying here to allocate scarce resources optimally and need to know the return on this spending to make the trade offs
- ▶ but: Economists know the price of everything and the value of nothing

## not perfect health

- ▶ there is a difference between a year of full health
- ▶ and a year lying in hospital
- ▶ or losing eye-sight
- ▶ not being able to do your own shopping, walking the stairs
- ▶ based on surveys, the 80.000 is discounted to take such effects into account
- ▶ then we get qaly's: quality adjusted life years

## which treatment covered?

- ▶ by this reasoning
  - ▶ a new cancer treatment that brings 0.5 qaly
  - ▶ at the price of 50.000 euro per treatment
  - ▶ should not be covered by basic insurance
  - ▶ because, once it is covered, people will use it
- ▶ this is what (almost) happened to the treatments for Fabry and Pompe
- ▶ then the 8 o'clock news opens with ...



## difficult choices

- ▶ should a 90 year old's qaly be valued the same as an 20 year old?
  - ▶ no, decreasing marginal returns and the 90 year old already had many years
  - ▶ yes, 90 year old has only few years left; the additional qaly is a big increase
- ▶ in the Netherlands, the analysis is not done at the patient level but at the treatment level
- ▶ average increase in qaly's is used to decide whether to cover treatment or not

## Other effects

- ▶ if we would be “more generous” and use 150.000 euro per qaly:
  - ▶ more treatments can be covered
  - ▶ seriously ill people do not have to buy expensive treatments themselves
  - ▶ either more money is spent on health care (and not education, welfare, development aid)
  - ▶ or less money is spent on other treatments that have a higher return
    - ▶ then the physician her/him self has to decide who gets treatment and who not
- ▶ pharmaceutical firms that have a monopoly (patent) on the drugs raise their price

# Conclusion

## policy implications

- ▶ allocating scarce resources leads to “unpleasant” choices
- ▶ economics makes these choices explicit
- ▶ this gives the impression that “we know the price of everything and the value of nothing”
- ▶ but if we do not make these choices as a society, physicians have to do it individually
  - ▶ very unpleasant for them
  - ▶ whether you get a life saving treatment or not, depends on your physician
  - ▶ may not be equipped to trade off treatment against money spent on education
- ▶ “financial considerations should play no role in health care”
  - ▶ not a great strategy
  - ▶ by definition not true: once you decide to spend your euro on a treatment, you do not spend it on something else